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Summary: The disappearance pattern of prostate-specific antigen frorn serum after a Standard radical prostatectomy
was studied in eight patients with cancer confined to the prostate. The results were used to plot an elimination
curve and calculate the best fit. A biphasic pattern was found with an average biological half-life of l .63 hours in
the -phase, and 4.63 days in the ß-phase. Based on these results it is concluded that determination of prostate-
specific antigen concentrations less than one month after a Standard radical prostato-vesiculectomy has no value for
the detection or exclusion of residual malignant processes.
Introduction
In 1971, a gamma seminoprotein was detected (1) in
seminal plasma, and subsequently isolated and charac-
terized by Li (2) and Sensabaugh (3). In 1979 Wang
(4) purified this protein from natural prostate tissue and
named it prostate-specific antigen. After the introduction
of commercial kits for the determination of prostate-
specific antigen, prostatic acid phosphatase was replaced
by prostate-specific antigen äs a tumour marker for pros-
tate cancer (5, 6). After radical prostatectomy äs a treat-
ment for localized cancer, the absence of residual tu-
mour (pT2-3N0M0) is indicated by a decrease of serum
prostate-specific antigen until it is undetectable by the
current generation of immunoassays for prostate-specific
antigen (6). In view of differences in the öbserved bio-
logical washout patterns and disappearance time of pros-
tate-specific antigen after a Standard radical prostatec-
tomy, we initiated the present study to determine the
biological half-life of prostate-specific antigen.
Methods and Patients
Prostate-specific antigen was measured by a solid-phase two-site
immunoenzymatic assay employing two monoclonal antibodies.
We used a commercial kit, Tandem R-E, from Hybritech (Hybri-
tech Ine, San Diego CA, USA), according to the instructions of the
manufacturer. The colorimetric measurements were performed on
a Photon II spectrophotometer.
Prostate-specific antigen excretion pattems were followed in eight
patients ranging from 59 to 75 years, suffering from prostatic can-
cer. The prostates were removed surgically, together with the semi-
nal vesicles. In all eight patients the cancer was confined to the
prostate; the bone scan was negative, and there was no lymph node
involvement at lymphadenectomy (pT2-3NoM0). The final patho-
logical stage and grade was pT2G2 (n = 2), pT3G2 (n = 4) and
pT3G3 (n = 2), respectively. During follow-up the prostate-specific
antigen concentration remained for at least one year after surgical
Intervention within the female ränge; during this time there was no
evidence ofdinical recurrence, based on digital rectal examination,
trans rectal ultra sonography of the prostate, bone-scan and ehest
X-ray. Venous blood was collected according to the following
scheine: before the Intervention two samples were taken at 9 a. m.
with a time interval of one day. The actual moment of removal of
the prostate was ealled T0. During and after the Intervention, blood
was collected every hour until two hours after T0, followed by
collection at 3, 6, 9 and 12 hours after T0. During the following
ten days one blood sample was taken each day, always at 9 a. m.
Until analysis all the serum samples were stored at —20 °C. Pros-
tate-specific antigen was determined when all the samples from
one patient were available.
For the statistical evaluation of the data we used a Computer pro-
gram ealled PCNONLIN NONUNEAR ESTIMATION from Stat-
istical Consulting Ine (Lexington, Kentucky, USA), which is able
to choose the right form of elimination through best fit of the elim-
ination curves of the individual patients (one, two or three compart-
ment model).
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Results and Discussion
During the surgical extirpation of the prostate, prostate-
specific antigen concentrations were increased to be-
tween three and ten times their starting levels. It was
noted that a biphasic disappearance curve resulted after
total removal of the prostate. The mean biological half-
life in the first phase ( -phase) was 1.63 hours (SD
0.69). After the first twenty-four hours the prostate-
specific antigen disappearance was more gradual. In this
phase (ß-phase) the biological half-life was 4.63 days
(SD 2.26). The graphic fit of the disappearance is shown
in figure l and the separate data of the individüal
patients are shown in table l.
The correctness of fit is very high (0.997). Data are ex-
pressed äs percentage of T0 values. In the literature sev-
eral other studies have been reported but they show no
general agreement äs to the disappearance rate. Our ob-
servations contradict those of Oesterling et al. (7), who
found a single phase elimination with a half-life of 3.15
days (SD 0.09.) determined with a log-linear regression
model. They stated that prostate-specific antigen con-
centrations were undetectable after 5 to 6 times the bio-
logical half-life, meaning that 16 days after the radical
prostatectomy the prostate-specific antigen concen-
trations were in the female ränge. Stamey et al. (6) found
a two-phase elimination: an -phase of 12.6 hours (SD
19.7) and a ß-phase of 2.2 days (SD 0.8). Their data
were calculated from the natural log of the prostate-
specific antigen concentration plotted against time.
These data fitted a two compartment model of first order
elimination kinetics. They also claimed that prostate-
specific antigen concentrations were no longer detect-
able after fourteen days. The fast decline in the first
phase, äs seen in our results, is probably based on com-
Tab. l Disappearance rates, expressed äs tj/2 of prostate-specific




































plex formation between liberated prostate-specific anti-
gen and mainly arantichymotrypsiii (10), and possibly
other acute phase proteins such äs a2-macroglobulin.
Examples of these complexes are deseribed by Chris-?
tensson (11).
There is some doubt äs to whether the Tandem- pros-
tate-specific antigen test method determines these com-
plexes. a2-Macroglobulin is known to encapsulate the
target protein at complex formation (11). This häppens
in such a way that no antiserum will detect prostate-
specific antigen bound to this acute phase protein. But
since the concentration of these coinplexes is low (12)
it is not to be expected that their presence will inflüence
our results to a great extent. The performance character-
istics of the Tandem- prostate-specific antigen ässay
are similar to those of the Tandem^R assay (13), and it
has been reported (10) that the latter kit also detects
prostate-specific antigen complexed to a^antichymo-







Fig. l Typical disappearance curve of prostate-specific antigen tion of initial concentration versus tirne. Values given are means
concentrations frorn serum after prostatectomy, expressed äs frac- ± l SD (n = 8).
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tech Tandem- , äs used by us, measures free prostate-
specific antigen, äs well äs prostate-specific antigen
bound to -antichymotrypsin. In the second phase the
slow decrease of prostate-specific antigen might be due
to a slow release of prostate-specific antigen from the
complexes and/or their gradual disappearance from
plasma. This issue will require further study.
Conclusion
In conclusion it can be stated that prostate-specific anti-
gen disappears after radical prostatectomy in accordance
with a biphasic excretion model, consisting of an a-
phase with a half-life of l .63 hours and a ß-phase with
a half-life of 4.63 days.
Based on our results and the assumption that 6 times the
half-life should elapse before a steady level has been
reached, we advise that determination of prostate-
specific antigen levels less than one month after a Stan-
dard radical prostato-vesiculectomy has no value for the
detection or exclusion of residual malignant processes.
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